Biohaven Pharma (BHVN) Misses Q4 EPS by 22c, Revenue Beats

Biohaven Pharma (NYSE: BHVN) reported Q4 EPS of ($2.32), $0.22 worse than the analyst estimate of ($2.10). Revenue for the quarter came in at $190 million versus the consensus estimate of $169.78 million.

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Biohaven Pharma (BHVN) PT Raised to $23 at RBC Capital
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79